Sign in

CIK 0001615219

  • Non-accelerated filer
  • Smaller reporting company

Decoy Therapeutics Inc.

Sign in to watch
Ticker
DCOY
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
465087339
Phone
+1 346-772-0346
Business address
2450 HOLCOMBE BLVD, SUITE J-608, HOUSTON, TX, 77021
Former names
Salarius Pharmaceuticals, Inc., Flex Pharma, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 44 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2017-07-26 Stacy Michelle Director Grant or award · Stock Option (right to buy) +12,000 12,000
2017-07-26 RANDLE STUART A Director Grant or award · Stock Option (right to buy) +12,000 12,000
2017-07-26 McVicar William K. President and CEO Grant or award · Stock Option (right to buy) +50,000 50,000
2017-07-26 MacKinnon Roderick Director Grant or award · Stock Option (right to buy) +12,000 12,000
2017-07-26 KOZIN MARC D Director Grant or award · Stock Option (right to buy) +12,000 12,000
2017-07-26 HUTT PETER BARTON Director Grant or award · Stock Option (right to buy) +12,000 12,000
2017-07-26 CAPELLO JEFFREY D Director Grant or award · Stock Option (right to buy) +12,000 12,000
2017-05-26 McVicar William K. President, R&D Grant or award · Stock Option (right to buy) +200,000 200,000
2017-01-18 Woo Elizabeth SVP, Investor Relations Grant or award · Stock Option (right to buy) +47,000 47,000
2017-01-18 Wessel Thomas Chief Medical Officer Grant or award · Stock Option (right to buy) +85,000 85,000
2017-01-18 McCabe John P. Chief Financial Officer Grant or award · Stock Option (right to buy) +67,000 67,000
2017-01-18 Lindemann Katharine Chief Operating Officer Grant or award · Stock Option (right to buy) +77,000 77,000
2017-01-18 Hadfield Robert General Counsel & Secretary Grant or award · Stock Option (right to buy) +57,000 57,000
2016-11-08 Westphal Christoph H President and CEO Purchase +7,000 $7.31 $51K 3,941,118
2016-11-07 Westphal Christoph H President and CEO Purchase +8,870 $5.70 $51K 3,934,118
2016-11-07 McCabe John P. VP of Finance & Treasurer Purchase +1,650 $6.01 $10K 1,650
2016-06-23 Westphal Christoph H President and CEO Purchase +2,700 $11.28 $30K 3,212,861
2016-06-22 Westphal Christoph H President and CEO Purchase +2,900 $11.03 $32K 3,210,161
2016-06-21 Westphal Christoph H President and CEO Purchase +2,800 $11.07 $31K 3,207,261
2016-06-20 Westphal Christoph H President and CEO Purchase +3,000 $11.37 $34K 3,204,461

Page 8 of 12 · 229 trades